Drug intelligence / Profile preview

cyclophosphamide + lenograstim

Development stage: Unknown
Lead developer: Takeda
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination of cyclophosphamide, an alkylating agent, and lenograstim, a recombinant human granulocyte colony-stimulating factor (rHuG-CSF). Cyclophosphamide works by interfering with DNA replication through its metabolite phosphoramide mustard, while lenograstim stimulates neutrophil production to reduce chemotherapy-induced neutropenia. This combination is used in cancer treatment, particularly for inflammatory breast cancer, where lenograstim helps mitigate the myelosuppressive effects of cyclophosphamide-containing chemotherapy regimens.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on cyclophosphamide + lenograstim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + lenograstim.

Explore the full profile